Kardestuncer T, Frumkin H. Systemic lupus erythematosus in relation to
environmental pollution: an investigation in an African-American community in North Georgia.
Arch Environ Health 1997;52:85–90.
Fjellner B. Drug-induced lupus erythematosus aggravated by oral therapy.
Acta Derm Venereol 1979;59:368–70.
Millard TP, Hawk JL, McGregor JM. Photosensitivity in lupus. Lupus
2000;9:3–10 [review].
Reidenberg MM, Durant PJ, Harris RA, et al. Lupus erythematosus-like disease
due to hydrazine. Am J Med 1983;75:365–70.
Pereyo N. Hydrazine derivatives and induction of systemic lupus erythematosus.
J Am Acad Dermatol 1986;14:514–5 [letter].
Nagata C, Fuyita, Iwata H, et al. Systemic lupus erythematosus: a case-control
epidemiologic study in Japan. Int J Dermatol 1995;34:333–7.
Minami Y, Sasaki Ti, Komatsu S, et al. Female systemic lupus erythematosus in
Miyagi Prefecture, Japan: a case-control study of dietary and reproductive factors. Tohoku
J Exp Med 1993;169:245–52.
Nagata C, Fuyita, Iwata H, et al. Systemic lupus erythematosus: a case-control
epidemiologic study in Japan. Int J Dermatol 1995;34:333–7.
Kardestuncer T, Frumkin H. Systemic lupus erythematosus in relation to
environmental pollution: an investigation in an African-American community in North Georgia.
Arch Environ Health 1997;52:85–90.
Comstock GW, Burke AE, Hoffman SC, et al. Serum concentrations of
alpha-tocopherol, beta-carotene, and retinol preceding the diagnosis of rheumatoid arthritis
and systemic lupus erythematosus. Ann Rheum Dis 1997;56:323–35.
Nagata C, Fuyita, Iwata H, et al. Systemic lupus erythematosus: a case-control
epidemiologic study in Japan. Int J Dermatol 1995;34:333–7.
Shigemasa C, Tanaka T, Mashiba H. Effect of vegetarian diet on systemic lupus
erythematosus. Lancet 1992;339:1177 [letter].
Minami Y, Sasaki Ti, Komatsu S, et al. Female systemic lupus erythematosus in
Miyagi Prefecture, Japan: a case-control study of dietary and reproductive factors. Tohoku
J Exp Med 1993;169:245–52.
Corman LC. The role of diet in animal models of systemic lupus erythematosus:
possible implications for human lupus. Semin Arthritis Rheum 1985;15:61–9
[review].
Clark WF, Parbtani A, Huff MW, et al. Flaxseed: a potential treatment for
lupus nephritis. Kidney Int 1995;48:475–80.
Prasad K. Hydroxyl radical-scavenging property of secoisolariciresinol
diglucoside (SDG) isolated from flax-seed. Mol Cell Biochem
1997;168:117–23.
Diumenjo MS, Lisanti M, Valles R, Rivero I. Allergic manifestations of
systemic lupus erythematosus. Allergol Immunopathol (Madr) 1985;13:323–6 [in
Spanish].
Nagata C, Fuyita, Iwata H, et al. Systemic lupus erythematosus: a case-control
epidemiologic study in Japan. Int J Dermatol 1995;34:333–7.
Carr RI, Tilley D, Forsyth S, et al. Failure of oral tolerance in (NZB X
NZW)F1 mice is antigen specific and appears to parallel antibody patterns in human systemic
lupus erythematosus (SLE). Clin Immunol Immunopathol 1987;42:298–310.
Rutkowska-Sak L, Legatowicz-Koprowska M, Ryzko J, Socha J. Changes in the
gastrointestinal system of children with inflammatory systemic connective tissue diseases.
Pediatr Pol 1995;70:235–41 [in Polish].
Carr R, Forsyth S, Sadi D. Abnormal responses to ingested substances in murine
systemic lupus erythematosus: apparent effect of a casein-free diet on the development of
systemic lupus erythematosus in NZB/W mice. J Rheumatol 1987;14 (suppl
13):158–65.
Bardana EJ Jr, Malinow MR, Houghton DC, et al. Diet-induced systemic lupus
erythematosus (SLE) in primates. Am J Kidney Dis 1982;1:345–52.
Roberts JL, Hayashi JA. Exacerbation of SLE associated with alfalfa ingestion.
N Engl J Med 1983;308(22):1361 [letter].
Malinow MR, McLaughlin P, Bardana EJ Jr, Craig S. Elimination of toxicity from
diets containing alfalfa seeds. Food Chem Toxicol 1984;22:583–7.
Hardy CJ, Palmer BP, Muir KR, et al. Smoking history, alcohol consumption, and
systemic lupus erythematosus: a case-control study. Ann Rheum Dis
1998;57:451–5.
Barry NN, McGuire JL, van Vollenhoven RF. Dehydroepiandrosterone in systemic
lupus erythematosus: relationship between dosage, serum levels, and clinical response. J
Rheumatol 1998;25:2352–6.
Van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of
systemic lupus erythematosus with dehyroepiandrosterone: 50 patients treated up to 12 months.
J Rheumatol 1998;25:285–9.
Van Vollenhoven RF, Engleman EG, McGuire JL. An open study of
dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum
1994;37:1305–10.
Van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in
systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized
clinical trial. Arthritis Rheum 1995;38:1826–31.
Van Vollenhoven RF, Park JL, Genovese MC, et al. A double-blind,
placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus
erythematosus. Lupus 1999;8:181–7.
van Hollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of
systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
J Rheumatol 1998;25:285–9.
Orner GA, Mathews C, Hendricks JD, et al. Dehydroepiandrosterone is a complete
hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in
rainbow trout. Carcinogenesis 1995;16:2893–8.
Metzger C, Mayer D, Hoffmann H, et al. Sequential appearance and
ultrastructure of amphophilic cell foci, adenomas, and carcinomas in the liver of male and
female rats treated with dehydroepiandrosterone. Taxicol Pathol
1995;23:591–605.
Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H
(A vy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res
1979;39:1129–32.
McNeil C. Potential drug DHEA hits snags on way to clinic. J Natl Cancer
Inst 1997;89:681–3.
Jones JA, Nguyen A, Strab M, et al. Use of DHEA in a patient with advanced
prostate cancer: a case report and review. Urology 1997;50:784–8.
Zumoff B, Levin J, Rosenfeld RS, et al. Abnormal 24-hr mean plasma
concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with
primary operable breast cancer. Cancer Res 1981;41:3360–3.
Skolnick AA. Scientific verdict still out on DHEA. JAMA
1996;276:1365–7 [review].
Sahelian R. New supplements and unknown, long-term consequences. Am J
Natural Med 1997;4:8 [editorial].
Casson PR, Santoro N, Elkind-Hirsch K, et al. Postmenopausal
dehydroepiandrosterone administration increases free insulin-like growth factor-I and
decreases high-density lipoprotein: a six-month trial. Fertil Steril
1998;70:107–10.
Kelley VE, Ferretti A, Izui S, Strom TB. A fish oil diet rich in
eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-1pr
mice. J Immunol 1985;134:2914–9.
Walton AJE, Snaith ML, Locniskar M, et al. Dietary fish oil and the severity
of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis
1991;50:463–6.
Westberg G, Tarkowski A. Effect of MaxEPA in patients with SLE. Scand J
Rheumatology 1990;19:137–43.
Comstock GW, Burke AE, Hoffman SC, et al. Serum concentrations of
alpha-tocopherol, beta-carotene, and retinol preceding the diagnosis of rheumatoid arthritis
and systemic lupus erythematosus. Ann Rheum Dis 1997;56:323–35.
Weimann BJ, Weiser H. Effects of antioxidant vitamins C, E, and beta-carotene
on immune functions in MRL/lpr mice and rats. Ann N Y Acad Sci
1992;669:390–2.
Ayres S Jr, Mihan R. Is vitamin E involved in the autoimmune mechanism?
Cutis 1978;21:321–5.
Ayres S Jr, Mihan R. Lupus erythematosus and vitamin E: an effective and
nontoxic therapy. Cutis 1979;23:49–54.
Yell JA, Burge S, Wojnarowska F. Vitamin E and discoid lupus erythematosus.
Lupus 1992;1:303–5.
Newbold PC. Beta-carotene in the treatment of discoid lupus erythematosus.
Br J Dermatol 1976;95:100–1.
Dubois EL, Patterson C. Ineffectiveness of beta-carotene in lupus
erythematosus JAMA 1976;236:138–9 [letter].
Welsh AL. Lupus erythematosus: Treatment by combined use of massive amounts of
pantothenic acid and vitamin E. Arch Dermatol Syphilol 1954;70:181–98.
Cochrane T, Leslie G. The treatment of lupus erythematosus with calcium
pantothenate and panthenol. J Invest Dermatol 1952;18:365–7.
Stefanescu M, Matache C, Onu A, et al. Pycnogenol efficacy in the treatment of
systemic lupus erythematosus patients. Phytother Res 2001;15:698–704.
Wang ZY. Clinical and laboratory studies of the effect of an antilupus pill on
systemic lupus erythematosus. Chung His I Chieh Ho Tsa Chih 1989;9:452,465–8
[in Chinese].
Ruan J, Ye RG. Lupus nephritis treated with impact therapy of cyclophosphamide
and traditional Chinese medicine. Chung Kuo Chung His I Chieh Ho Tsa Chih
1994;14:260, 276–8 [in Chinese].
Chen JR, Yen JH, Lin CC, et al. The effects of Chinese herbs on improving
survival and inhibiting anti-ds DNA antibody production in lupus mice. Am J Chin Med
1993;21:257–62.
Wanzhang Q. Clinical observations on Tripterygium wilfordii in the
treatment of 26 cases of discoid lupus erythematosus. J Trad Chin Med
1983;3:131–2.
Wanzhang Q. Tripterygium wilfordii hook F. in systemic lupus
erythematosus. Report of 103 cases. Chin Med J 1981;94:827–34.
Chou WC, Wu CC, Yang PC, Lee YT. Hypovolemic shock and mortality after
ingestion of Tripterygium wilfordii hook F: a case report. Int J Cardiol
1995;49:173–7.
Huang L, Feng S, Wang H. Decreased bone mineral density in female patients
with systemic lupus erythematosus after long-term administration of Tripterygium
wilfordii Hook. F. Chinese Med J 2000;113:159–61.
Klepser T, Nisly N. Astragalus as an adjunctive therapy in immunocompromised
patients. Alt Med Alert 1999;Nov:125–8 [review].